DUBIN STEVE 4

What Happened

• Steve Dubin, a director of Adicet Bio, was granted a derivative equity award of 4,200 shares on 2026-06-21. The shares were issued at $0.00 (no cash paid) and reported on a Form 4 filed 2026-06-23. This is an equity grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-21; Form 4 filed: 2026-06-23 (timely; Form 4s are due within two business days).
• Award: 4,200 shares; price reported: $0.00; total cash exchanged: $0.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: shares vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders following the grant date, subject to Dubin’s continued service on the board.
• Transaction code: A (award/grant); classified as a derivative award in the filing.

Context

• This appears to be a routine director equity grant subject to time-based vesting; such awards are common as board compensation and do not reflect an immediate cash outflow or an open-market purchase. For retail investors, note that grants signal compensation practices but are not direct buying or selling of stock.